He Jiankui plans gene editing for Alzheimer’s after prison term

Chinese scientist He Jiankui, who served time in prison for creating the world’s first gene-edited babies, now intends to pursue similar work to combat Alzheimer’s disease. He has criticized Silicon Valley’s efforts in the field as a “Nazi eugenic experiment.” This development revives ethical debates in biotechnology.

In 2018, He Jiankui made headlines by announcing at a scientific conference in Hong Kong that he had produced the world’s first gene-edited babies. The soft-spoken researcher confirmed the reports amid a tense atmosphere in the packed auditorium, adjusting his microphone before addressing the audience.

His actions led to his imprisonment in China for violating regulations on gene editing. Now, years later, He Jiankui is preparing to resume such experiments, this time targeting Alzheimer’s disease with the goal of eradicating it.

He has voiced strong objections to ongoing projects in Silicon Valley, labeling them a “Nazi eugenic experiment.” This perspective underscores the ongoing ethical tensions surrounding gene-editing technologies like CRISPR, which He pioneered in his controversial work.

The announcement, detailed in a recent Wired article, highlights the persistent global divide on the boundaries of genetic intervention. While He’s past work sparked international condemnation for ethical lapses, his renewed ambitions signal a bold push forward in medical applications, though under heightened scrutiny.

Labaran da ke da alaƙa

Scientists at Virginia Tech using CRISPR tools to improve memory in aged rats, illustrating potential for combating cognitive decline.
Hoton da AI ya samar

Virginia Tech team improves memory in aged rats with targeted gene-editing

An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya

Scientists at Virginia Tech report that tuning specific molecular pathways with CRISPR-based tools improved memory in older rats across two peer‑reviewed studies, pointing to possible routes for tackling age‑related cognitive decline.

Health economics specialist Martin Morgenstern stated in an interview that genetic editing will transform medical treatments in the coming decades. According to him, technologies like CRISPR will allow altering specific genes to combat conditions like high cholesterol. This approach promises to be more precise than traditional medications, though it carries inherent risks.

An Ruwaito ta hanyar AI

At October's Pandemic Research Alliance Symposium, researcher Wei Zhao presented an innovative concept using CRISPR to combat influenza. The idea targets the virus's replication process, potentially halting its spread. This development highlights ongoing efforts in gene-editing research against relentless flu strains.

A new genetic study has identified 331 genes essential for transforming stem cells into brain cells, including a novel gene linked to neurodevelopmental disorders. Led by scientists at the Hebrew University of Jerusalem, the research highlights how early genetic disruptions can lead to conditions like autism and developmental delay. The findings, published in Nature Neuroscience, also reveal patterns in how these disorders are inherited.

An Ruwaito ta hanyar AI An Binciki Gaskiya

Researchers have developed a genomic mapping technique that reveals how thousands of genes work together to influence disease risk, helping to bridge gaps left by traditional genetic studies. The approach, described in a Nature paper led by Gladstone Institutes and Stanford University scientists, combines large-scale cell experiments with population genetics data to highlight promising targets for future therapies and deepen understanding of conditions such as blood disorders and immune-mediated diseases.

Researchers have demonstrated that restoring levels of a key brain energy molecule can reverse advanced Alzheimer's disease in mouse models, repairing damage and restoring cognitive function. The study, published on December 22, challenges the long-held view that the condition is irreversible. Findings from human brain tissue support the approach's potential relevance to patients.

An Ruwaito ta hanyar AI

Consciousness expert Steven Laureys has joined Hangzhou Normal University, praising China's opportunities in science amid challenging times in the US. He highlights China's efficient resource unification and collaborative push.

 

 

 

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi